Professional Essentials

  • Patients Will Be Asking

Could my favorite cocktail give me more than alcohol poisoning?

  • US Professional News
  • FULLTEXT

NPs, PAs boost productivity: survey

  • US Professional News
  • FULLTEXT

Physician must stop marketing 3-parent baby technique

  • US Professional News
  • FULLTEXT

CMS policy spurs outpatient knee replacement

  • US Professional News
  • FULLTEXT

Adams confirmed as surgeon general

  • US Professional News
  • FULLTEXT

Most Americans pleased with their provider

View more

New in Dermatology

  • Clinical Essentials from J Eur Acad Dermatol Venereol
  • 1 comment

Psoriasis: is apremilast safe and effective in real-world practice?

Real-world data on apremilast efficacy are scarce.

  • Clinical Essentials from J Invest Dermatol
  • 1 comment

Psoriasis: British registry study nixes link between biologics, serious infection

Risk for serious infection should not affect treatment selection.

  • Clinical Essentials from Epilepsia
  • 1 comment

Epilepsy: newer AEDs carry lower risk for SJS/TEN

A case-control study of 2400 patients from the UK-based Clinical Practice Research Datalink.

  • Clinical Essentials from CA Cancer J Clin
  • 1 comment
  • FULLTEXT

AJCC unveils new melanoma staging system

Updated framework for staging cutaneous melanoma.

  • Clinical Essentials from J Am Acad Dermatol
  • 1 comment
  • FULLTEXT

Atopic dermatitis: systematic review supports limiting oral steroids

An analysis of 52 reviews and 12 studies.

Skin Disease Vitals for October 2017
  • Vitals
  • 1 comment

Skin Disease Vitals for October 2017

MTX vs TNFi in pediatric psoriasis | Ixekizumab is effective, safe in plaque psoriasis.

  • Clinical Essentials from Br J Dermatol
  • 1 comment

Psoriasis: 2nd-line guselkumab performs well in NAVIGATE trial

Randomized trial of patients with inadequate response to ustekinumab.

  • Clinical Essentials from Br J Dermatol
  • 1 comment

Psoriasis: ixekizumab efficacy confirmed in integrated analysis

Summary of phase 3 data.

  • Clinical Essentials from J Eur Acad Dermatol Venereol
  • 1 comment

Facial psoriasis linked to reduced QoL, but ixekizumab helps

Combined results of UNCOVER-2 and UNCOVER-3 trials.

  • Clinical Essentials from J Am Acad Dermatol
  • 1 comment
  • FULLTEXT

Psoriasis: early response to MTX portends 4-mo outcome

Early response prediction may limit safety risk.

  • Clinical Essentials from J Am Acad Dermatol
  • 1 comment
  • FULLTEXT

Nail psoriasis: adalimumab shows promise in phase 3 trial

First placebo-controlled clinical trial of adalimumab for nail psoriasis as primary endpoint.

  • Clinical Essentials from J Am Acad Dermatol
  • 1 comment
  • FULLTEXT

Melasma: promising results from tranexamic acid

Evidence from a controlled study.

  • Clinical Essentials from J Am Acad Dermatol
  • 1 comment

Melanoma: an improved recognition strategy?

The UD sign is not generally taught but appears to be useful for melanoma recognition.

  • Clinical Essentials from PLoS ONE
  • no comment

Rosacea tied to an increased risk for CKD

Findings warrant careful monitoring and avoidance of nephrotoxic agents.